Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

24.70EUR
1 Aug 2013
Price Change (% chg)

€0.61 (+2.53%)
Prev Close
€24.09
Open
€24.09
Day's High
€24.95
Day's Low
€24.02
Volume
69,783
Avg. Vol
47,732
52-wk High
€24.95
52-wk Low
€15.19

GRLSbn.MC

Chart for GRLSbn.MC

About

Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products. Its activities are structured in four segments:... (more)

Overall

Beta: 0.47
Market Cap (Mil.): €9,905.15
Shares Outstanding (Mil.): 343.78
Dividend: 0.20
Yield (%): 0.63

Financials

  GRLSbn.MC Industry Sector
P/E (TTM): 37.97 37.93 37.76
EPS (TTM): 0.84 -- --
ROI: 5.52 19.48 18.76
ROE: 15.40 20.17 19.59
Search Stocks

Spain's Grifols H1 net profit up 37 pct

MADRID, July 31 - Spanish pharmaceutical company Grifols, the world's third-largest blood products maker, said on Wednesday net profit rose 37 percent in the first half from a year earlier to 182.8 million euros ($242 million), boosted by overseas sales, especially in the United States.

31 Jul 2013

Grifols signs deal to license Aradigm's Pulmaquin

MADRID, May 21 - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.

21 May 2013

Spain's Grifols says Q1 net profit up 19 pct y/y

MADRID, May 2 - Spanish pharmaceutical company Grifols said on Thursday net profit rose 19 percent in the first quarter of 2013 from a year earlier to 115.7 million euros ($152.6 million), boosted by overseas sales, especially Latin America and Asia.

02 May 2013

Spain's Grifols reports fivefold increase in 2012 profit

MADRID, Feb 28 - Spanish pharmaceutical company Grifols reported a more than fivefold rise in full-year profit for 2012 to 257 million euros ($336.90 million), buoyed by its acquisition of U.S. firm Talecris last June and its wide geographic presence outside its depressed home market.

28 Feb 2013

Earnings vs. Estimates

Search Stocks